Latest Sobi News & Updates

See the latest news and media coverage for Sobi. We track all announcements, press releases, and industry mentions in real time, all in one place.

Sobi

International biopharmaceutical company focused on rare diseases

sobi.com

Headquarters: Stockholm, Sweden
Company type: Public company
Number of employees: 2,400–5,000
Industry: Pharmaceuticals

Last updated October 29

Latest news about Sobi

In short: Sobi reported stronger-than-expected Q3 2026 results, raised its forecast, and announced CEO succession.

Company announcements

October 28 Sobi

Sobi acquires Pint Pharma

The acquisition strengthens Sobi's presence in rare disease markets across Latin America, building on a partnership since 2021.

October 27 Sobi

Sobi upgrades full-year revenue outlook to high-teens growth at CER

Q3 results show +26% ex-royalty revenue growth with strong Altuvoct and Aspaveli performance alongside new product approvals in Japan.

October 16 Sobi

Sobi receives positive CHMP opinion for TRYNGOLZA for severe hypertriglyceridemia

The EMA committee recommends the drug extension. A final EC decision is expected in Q4 2026 based on Phase 3 CORE studies.

August 10 Sobi

Sobi partners with Innate Pharma to license lacutamab

The deal includes a USD 75 million upfront payment, with Sobi obtaining exclusive global commercialization rights and potential full development rights after positive Phase 3 results.

Media coverage

October 29 Yahoo Finance

Late-breaking Phase 3 REDUCE-2 data show clinically meaningful and durable serum urate lowering with pozdeutinurad

Sobi® (STO: SOBI) today announced the presentation of late-breaking data from the pivotal Phase 3 REDUCE-2 study of pozdeutinurad (AR882), an investigational next-generation once-daily oral...

October 29 Dagens industri

Ekholm proposed as new chairman of Sobi

Börje Ekholm appears set to add yet another board position to his post-Ericsson life. On Thursday evening, he is proposed to take over the chairmanship...

October 27 Pharmafile

Sobi’s olezarsen recommended for EU approval in severe hypertriglyceridaemia

Sobi’s olezarsen (TRYNGOLZA) has received a positive opinion from the European Medicines Agency’s Committee for Medicinal ...

October 27 AffärsVärlden

Sobi raises forecast after strong results

The pharmaceutical company Sobi reports a stronger third quarter and increases its income forecast for the year.

Never miss news about Sobi

Track Sobi and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Sobi competitors & trending companies

Browse news for competitors to Sobi and other trending companies.